Clinical Trial Update: Study to Examine the Clinical Efficacy and the Nonsteroidal Anti-inflammatory Drug (NSAID)-Sparing Effect of Secukinumab Over 16 Weeks in Patients With Ankylosing Spondylitis [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update evaluating efficacy and NSAID-sparing effect of secukinumab in ankylosing spondylitis; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis

Drugs mentioned

• Secukinumab (secukinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Ankylosing Spondylitis | Phase 4 | Status: COMPLETED | Results posted: 2020-10-09